ArticleScientific reports2026
Synthesis, SAR, and multi-target evaluation of isonicotinoyl hydrazones as potent MPO/AChE inhibitors and metal chelators for Alzheimer's disease.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isonicotinoyl hydrazone derivatives (1-20) were synthesized and evaluated for their inhibitory activities against myeloperoxidase (MPO) and acetylcholinesterase (AChE), antioxidant activity, metal ion chelation, regulation of reactive oxygen species, and cytoprotective activity, with the aim of identifying multi-target therapeutic candidates for Alzheimer's disease. In this study, 9 exhibited a free radical scavenging activity of 93% and showed strong inhibitory effects against MPO and AChE, with inhibition rates of 90% and 73%, respectively. An in-depth structure-activity relationship analysis revealed that 9 possesses a favorable pharmacological balance between lipophilicity and electronic properties. Moreover, 9 effectively chelated Cu
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.